We read with great interest the article by Veraldi et Al. on the relationship between Pityriasis Rosea (PR) and Covid 19 infection (1). In response to the above mentioned article we would like to share our experience on a case of Pityriasis Rosea diagnosed after Covid 19 infection with atypical clinical presentation and low responsiveness to conventional treatments. Pityriasis rosea of Gibert (PR) is an erythematous-papulosquamous dermatosis that frequently occurs in young adults; it is a common self-limiting rash,with a typical duration of 6-8 weeks (2). It usually starts with a herald patch on the trunk and progresses along the langer lines to a generalized rash over the trunk and limbs, giving it a "Christmas tree" appearance. The diagnosis is usually based on clinical and physical examinations findings (3). The etiopathogenesis of PR is still unknown, but it may be associated with upper respiratory tract infections. (3) Particularly, a viral etiology was proposed since intranuclear and intracytoplasmic virus-like particles were observed through microscopy; the most common viruses linked to PR are human herpesvirus-6 and -7 (HHV-6 and -7) (3-4). It has been recently proposed that a new viral trigger of PR may be the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1,4). Indeed, several patients affected by infection due to COVID 19 presented an atypical PR (5). We herein report our experience about the relationship between PR and Covid 19. This article is protected by copyright. All rights reserved.
Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies?